Functional network composed of 1,219 genes for Schizophrenia-- a literature data mining and enrichment analysis-Journal of Psychiatry and Brain Science-CSCIED科技核心评价数据库-手机版

Functional network composed of 1,219 genes for Schizophrenia-- a literature data mining and enrichment analysis

Functional network composed of 1,219 genes for Schizophrenia-- a literature data mining and enrichment analysis

ES评分 0 浏览量：1080 下载量：0

DOI	10.20900/jpbs.20160004
刊名	Journal of Psychiatry and Brain Science JPBS
年，卷(期)	2016, 1(1)
作者	Shunan Li, Benjamin H Lehrman, Hongbao Cao, Lydia C Manor*,
作者单位	6342 SW Macadam Ave, Portland, OR 97239 ; 600 S Paulina St, Chicago, IL 60612 ; 5635 Fishers LnRockville, MD 20852 ;
Abstract	Background: Over the past decade, numerous studies have focused on identifying genetic factors associated with schizophrenia (SCZ).Sample variations, such as size, population, race, disease status, and data processing methods resulted in selection differences. Nevertheless, no systemic study has been completed to summarize these reports and provide an objective full list of genes with a reported association to SCZ. Method: We conducted a literature data mining (LDM) of over 13,515 articles covering publications from 1958 to Feb. 2016. These articles reported multiple types of marker-disease associations between 1,219 genes and SCZ. Then we conducted a gene set enrichment analysis (GSEA) and a sub-network enrichment analysis (SNEA) to study the functional profile and validate the pathogenic significance of these genes to SCZ. Finally, we presented additional results from the systemic review, including publication date, quality scores, and authoraffiliations. Results: All of these genes have been demonstrated to present multiple mutations associating with SCZ, some of which were supported by a large number of high quality articles. Enrichment analyses showed that many psychiatric and neuropathic pathways/groups related to SCZ have been significantly enriched by these genes and that they are functionally associated with each other. Conclusion: Our results indicate that these genesmay operate as a functional biomarker network influencing the development of SCZ, and thatLDM together with GSEA and SNEA could serve as an effective approach in finding these potential target genes.
基金项目
页码	-

参考文献
相关文献

1.Abdolmaleky HM, Nohesara S, Ghadirivasfi M, Lambert AW, Ahmadkhaniha H, Ozturk S, Wong CK, Shafa R, Mostafavi A, Thiagalingam S (2014). DNA hypermethylation of serotonin transporter gene promoter in drug naïve patients with schizophrenia . Schizophrenia Research, 152:(2-3):373-380.View Article

2.Agha Z, Iqbal Z, Azam M, Siddique M, Willemsen MH, Kleefstra T, Zweier C, de Leeuw N, Qamar R, van Bokhoven H (2014). A complex microcephaly syndrome in a Pakistani family associated with a novel missense mutation in RBBP8 and a heterozygous deletion in NRXN1. Gene, 538(1):30-35.View Article

3.Ando S, Clement S, Barley EA, Thornicroft G (2011). The simulation of hallucinations to reduce the stigma of schizophrenia: a systematic review. Schizophr Res. 133(1-3):8-16.View Article

4.Balu DT, Li Y, Puhl MD, Benneyworth MA, Basu AC, Bolshakov VY, Coyle JT, Balu DT, Puhl MD, Benneyworth MA, Basu AC, Coyle JT, Takagi S (2013).Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proceedings of the National Academy of Sciences of the United States of America, 110(26):E2400-E2409.View Article

5.Barry G, Vanichkina DP, Taft RJ, Mattick JS, Briggs JA, Nayler SP, Wolvetang EJ, Poth EM, Blackshaw S, Beveridge NJ, Cairns MJ, Beveridge NJ, Cairns MJ, Ratnu VS, Bredy TW, Nones K, Hu J, Nakagawa S, Rigo F, Mattick JS, Mattick JS (2014). The long non-coding RNA Gomafu is acutely regulated in response to neuronal activation and involved in schizophrenia-associated alternative splicing. Molecular Psychiatry, 19(4):486-494.View Article

6.BeveridgeA(2002). The Creation of Psychopharmacology. J R Soc Med, 95(11): 568–569.

7.Bliksted V, Ubukata S, Koelkebeck K (2016). Discriminating autism spectrum disorders from schizophrenia by investigation of mental state attribution on an on-line mentalizing task: A review and meta-analysis. Schizophr Res. 171(1-3):16-26.View Article

8.Boneberg EM, von Seydlitz E, Pröpster K, Watzl H, Rockstroh B, Illges H (2006).D3 dopamine receptor mRNA is elevated in T cells of schizophrenic patients whereas D4 dopamine receptor mRNA is reduced in CD4 +-T cells. Journal of Neuroimmunology, 173(1-2):180-187.View Article

9.Braff DL, Geyer MA, Swerdlow NR (2001). Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl). 156(2-3):234-58.View Article

10.Chakraborty A, Xu J, Snyder SH, Chakraborty A, Latapy C, Beaulieu J-M, Snyder SH, Snyder SH, Chakraborty A (2014). Inositol hexakisphosphate kinase-1 regulates behavioral responses via GSK3 signaling pathways. Molecular Psychiatry, 19(3):284-293.View Article

11.Chen SL, Lee SY, Chang YH, Chen SH, Chu CH, Wang TY, Chen PS, Lee IH, Yang YK, Hong JS, Lu RB (2014). The BDNF Val66Met polymorphism and plasma brain-derived neurotrophic factor levels in Han Chinese patients with bipolar disorder and schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 51(0):99-104.View Article

12.Cheng J, Wang Y, Zhou K, Wang L, Li J, Zhuang Q, Xu X, Xu L, Zhang K, Dai D, Zheng R, Li G, Zhang A, Gao S, Duan S (2014). Male-specific association between dopamine receptor D4 gene methylation and schizophrenia. PLoS ONE,9(2). DOI: 10.1371/journal.pone.0089128View Article

13.Danielyan A, Nasrallah HA (2009). Neurological disorders in schizophrenia, PsychiatrClin North Am. 32(4):719-57.

14.Debanne D, Campanac E, Bialowas A, Carlier E, Alcaraz G (2009). Axon physiology.Physiol Rev, 91(2): 555-602.

15.Deng C (2013).Effects of Antipsychotic Medications on Appetite, Weight, and Insulin Resistance. Endocrinology and Metabolism Clinics of North America, 42(3):545-563.

16.Du L, Merali Z, Poulter MO, Palkovits M, Faludi G, Anisman H (2014). Catechol-O-methyltransferase Val158Met polymorphism and altered COMT gene expression in the prefrontal cortex of suicide brains. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 50:178-183.View Article

17.Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR (2003). The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 112(2):257-69.View Article

18.El Hage C, Bédard AM, Samaha AN (2015). Antipsychotic treatment leading to dopamine supersensitivity persistently alters nucleus accumbens function. Neuropharmacology. 99:715-25. doi: 10.1016/j.neuropharm.2015.03.012.View Article

19.Elena Ivleva,2 Gunvant Thaker,3 and Carol A. Tamminga (2008).Comparing Genes and Phenomenology in the Major Psychoses: Schizophrenia and Bipolar 1 Disorder, Schizophr Bull. 34(4): 734–742.View Article

20.Fatemi SH, Fatemi SH, Fatemi SH (2013). Cerebellum and autism. Cerebellum, 12(5):778-779View Article

21.Folsom TD, HosseinFatemi S (2012). The involvement of Reelin in neurodevelopmental disorders. Neuropharmacology, 68(0):122-135.

22.Fuxe K, Marcellino D, Leo G, Agnati LF (2010). Molecular integration via allosteric interactions in receptor heteromers. A working hypothesis. Current Opinion in Pharmacology, 10(1):14-22.View Article

23.Graziane NM, Yuen EY, Yan Z (2009). Dopamine D4 Receptors Regulate GABAA Receptor Trafficking via an Actin/Cofilin/Myosin-dependent Mechanism. Journal of Biological Chemistry, 284(13):8329-8336.View Article

24.Gu L, Long J, Yan Y, Chen Q, Pan R, Xie X, Mao X, Hu X, Wei B, Su L (2013). HTR2A-1438A/G polymorphism influences the risk of schizophrenia but not bipolar disorder or major depressive disorder: a meta-analysis. Journal of Neuroscience Research, 91(5):623-633.View Article

25.Guest PC, Salim K, Skynner HA, George SE, Bresnick JN, McAllister G (2000). Identification and characterization of a truncated variant of the 5-hydroxytryptamine 2A receptor produced by alternative splicing. Brain Research, 876(1-2):238-244.View Article

26.Hayashi-Takagi A, Sawa A, Hayashi-Takagi A, Nakamura M, Kasai H, Hayashi-Takagi A, Araki Y, Huganir RL, Sawa A, Vollrath B, Duron SG, Campbell DA, Yan Z (2014). PAKs inhibitors ameliorate schizophrenia-associated dendritic spine deterioration in vitro and in vivo during late adolescence. Proceedings of the National Academy of Sciences of the United States of America, 111(17):6461-6466.View Article

27.Herson M (2011). Etiological considerations. Adult psychopathology and diagnosis. John Wiley & Sons. ISBN 9781118138847View Article

28.Hill M,Shannahan K,Jasinski S,Macklin EA, Raeke L,Roffman JL,Goff DC(2011). Folatesupplementation in schizophrenia: A possible role for MTHFR genotype. Schizophrenia Research, 127(1-3):41-45.

29.Houston I, Peter CJ, Mitchell A, Rogaev E, Akbarian S, Straubhaar J (2013). Epigenetics in the human brain. Neuropsychopharmacology, 38(1):183-197.View Article

30.Howes OD, Kapur S (2009). The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull, 35(3):549-62.View Article

31.Hu CY, Qian ZZ, Gong FF, Lu SS, Feng F, Wu YL, Yang HY, Sun YH (2015). Methylenetetrahydrofolater eductase (MTHFR) polymorphism susceptibility to schizophrenia and bipolar disorder: an updated meta-analysis. Journal of Neural Transmission, 122(2):307-320.View Article

32.Ito C (2004). The role of the central histaminergic system on schizophrenia. Drug News & Perspectives 17 (6): 383–7.View Article

33.Jääskeläinen E, Haapea M, Rautio N, Juola P, Penttilä M, Nordström T, Rissanen I1, Husa A, Keskinen E, Marttila R, Filatova S, PaasoTM,Koivukangas J, Moilanen K, Isohanni M, Miettunen J (2015). Twenty Years of Schizophrenia Research in the Northern Finland Birth Cohort 1966: A Systematic Review. Schizophr Res Treatment, 2015:524875.View Article

34.Joshi D, Fullerton JM, Weickert CS (2014). Elevated ErbB4 mRNA is related to interneuron deficit in prefrontal cortex in schizophrenia. Journal of Psychiatric Research, 53(1):125-132.View Article

35.Kanazawa T, Glatt SJ, Kia-Keating B, Yoneda H, Tsuang MT (2007). Meta-analysis reveals no association of the Val66Met polymorphism of brain-derived neurotrophic factor with either schizophrenia or bipolar disorder. Psychiatric Genetics, 17(3):165-170.View Article

36.Khoddami M, Nadri H, Moradi A, Sakhteman A (2015). Homology modeling, molecular dynamic simulation, and docking based binding site analysis of human dopamine (D4) receptor. Journal of Molecular Modeling, 21(2):36View Article

37.Kret ME, Ploeger A (2015). Emotion processing deficits: A liability spectrum providing insight into comorbidity of mental disorders. Neuroscience and Biobehavioral Reviews, 52:153-171.View Article

38.Kroeger KM, Pfleger KDG, Eidne KA (2003). G-protein coupled receptor oligomerization in neuroendocrine pathways. Frontiers in Neuroendocrinology, 24(4):254-278.View Article

39.Lee KW, Woon PS, Teo YY, Sim K (2012). Genome wide association studies (GWAS) and copy number variation (CNV) studies of the major psychoses: What have we learnt?. Neuroscience and Biobehavioral Reviews, 36(1):556-571.View Article

40.Leonard S, Freedman R (2006). Genetics of Chromosome 15q13-q14 in Schizophrenia. Biological Psychiatry, 60(2):115-122.View Article

41.Liao Q, Wang Y, Cheng J, Dai D, Zhou X, Zhang Y, Gao S, Duan S (2015). DNA methylation patterns of protein coding genes and long noncoding RNAs in female schizophrenic patients. European Journal of Medical Genetics, 58(2):95-104.View Article

42.Lindenmayer JP, Khan A, Lachman H, McGurk SR, Goldring A, Thanju A, Kaushik S (2015). COMT genotype and response to cognitive remediation in schizophrenia. Schizophr Res. Oct; 1-2(168):279-84. doi: 10.1016/j.schres.2015.07.037.View Article

43.Luoni A, Berry A, Calabrese F, Capoccia S, Bellisario V, Gass P, Cirulli F, Riva MA (2014). Delayed BDNF alterations in the prefrontal cortex of rats exposed to prenatal stress:Preventive effect of lurasidone treatment during adolescence. European Neuropsychopharmacology, 24(6):986-995.View Article

44.Neddens J, Fish KN, Tricoire L, Vullhorst D, Shamir A, Chung W, Lewis DA, McBain CJ, Buonanno A (2011). Conserved Interneuron-Specific ErbB4 Expression in Frontal Cortex of Rodents, Monkeys, and Humans: Implications for Schizophrenia. Biological Psychiatry, 70(7):636-645.View Article

45.Nohesara S, Ghadirivasfi M, Mostafavi S, Eskandari MR, Ahmadkhaniha HR, Thiagalingam S, Abdolmaleky HM (2011). DNA hypomethylation of MB-COMT promoter in the DNA derived from saliva in schizophrenia and bipolar disorder. Journal of Psychiatric Research, 45(11):1432-1438.View Article

46.Owen MJ, Sawa A, Mortensen PB(2016). Schizophrenia.Lancet.Jan 14. pii: S0140-6736(15)01121-6. doi: 10.1016/S0140-6736(15)01121-6.View Article

47.Paulsen JS, Heaton RK, Sadek JR, Perry W, Delis DC, Braff D, Kuck J, Zisook S, Jeste DV (1995). The nature of learning and memory impairments in schizophrenia.JIntNeuropsychol Soc. 1(1):88-99.View Article

48.Pearson-Fuhrhop KM, Minton B, Acevedo D, Cramer SC, Shahbaba B, Cramer SC (2013). Genetic Variation in the Human Brain Dopamine System Influences Motor Learning and Its Modulation by L-Dopa. PLoS ONE, 4(8):e61197.View Article

49.Penzes P, Cahill ME, Jones KA, Vanleeuwen J-E, Woolfrey KM, Penzes P (2011). Dendritic spine pathology in neuropsychiatric disorders. Nature Neuroscience, 14(3):285-293.View Article

50.Pich EM, Collo G (2015). Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective agents. European Neuropsychopharmacology, 25(9):1437-1447.View Article

51.Porteous DJ, Thomson PA, Millar JK, Evans KL, Soares DC, Hennah W, McCarthy S, McCombie WR, Clapcote SJ, Korth C, Brandon NJ, Sawa A, Kamiya A, Roder JC, Lawrie SM, McIntosh AM, St Clair D, Blackwood DH (2014). DISC1 as a genetic risk factor for schizophrenia and related major mental illness: Response to Sullivan. Molecular Psychiatry, 19(2):141-143.View Article

52.Roffeei SN, Mohamed Z, Reynolds GP, Said MA, Hatim A, Mohamed EH, Aida SA, Zainal NZ (2014). Association of FTO, LEPR and MTHFR gene polymorphisms with metabolic syndrome in schizophrenia patients receiving antipsychotics. Pharmacogenomics, 15(4):477-485.View Article

53.Sacchi S, Rosini E, Pollegioni L, Molla G, Sacchi S, Rosini E, Pollegioni L, Molla G (2013). D-Amino acid oxidase inhibitors as a novel class of drugs for schizophrenia therapy. Current Pharmaceutical Design, 19(14):2499-2511.View Article

54.Schmidt U, Buell DR2, Ionescu IA2, Gassen NC3, Holsboer F4, Cox MB5, Novak B2, Huber C2, Hartmann J6, Schmidt MV6, Touma C6, Rein T3,Herrmann L2 (2015). A role for synapsin in FKBP51 modulation of stress responsiveness: Convergent evidence from animal and human studies. Psychoneuroendocrinology. 52:43-58.View Article

55.Schroeder A, Buret L, Hill RA, van den Buuse M (2015). Gene-environment interaction of reelin and stress in cognitive behaviours in mice: Implications for schizophrenia. Behavioural Brain Research, 287:304-314.View Article

56.Sequeira PA, Martin MV, Vawter MP (2012). The first decade and beyond of transcriptional profiling in schizophrenia. Neurobiology of Disease, 45(1):23-36.View Article

57.Serper MR1, Alpert M, Richardson NA, Dickson S, Allen MH, Werner A (1995). Clinical effects of recent cocaine use on patients with acute schizophrenia. Am J Psychiatry. 152(10):1464-9.View Article

58.Serper MR1, Chou JC, Allen MH, Czobor P, Cancro R (1999). Symptomatic overlap of cocaine intoxication and acute schizophrenia at emergency presentation. Schizophr Bull. 25(2):387-94.View Article

59.Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT,Hjaltason O, Birgisdottir B, Jonsson H, Gudnadottir VG, Gudmundsdottir E, Bjornsson A, Ingvarsson B, Ingason A, Sigfusson S, Hardardottir H, Harvey RP, Lai D, Zhou M, Brunner D, Mutel V, Gonzalo A, Lemke G, Sainz J, Johannesson G, Andresson T, Gudbjartsson D, Manolescu A, Frigge ML, Gurney ME, Kong A, Gulcher JR, Petursson H, Stefansson K (2002). Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 71(4):877-92.View Article

60.Strick CA1, Li C, Scott L, Harvey B, Hajós M, Steyn SJ, Piotrowski MA, James LC, Downs JT, Rago B, Becker SL, El-Kattan A, Xu Y, Ganong AH, Tingley FD 3rd,Ramirez AD, Seymour PA, Guanowsky V, Majchrzak MJ, Fox CB, Schmidt CJ, Duplantier AJ (2011). Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain.Neuropharmacology.2011Oct-Nov;61(5-6):1001-15.View Article

61.Susanne Nikolaus, Hubertus Hautzel1, Hans-Wilhelm Müller (2014). Neurochemical dysfunction in treated and nontreated schizophrenia-A retrospective analysis of in vivo imaging studies. Reviews in the Neurosciences, 25(1):25-96.View Article

62.Swerdlow NR1, Weber M, Qu Y, Light GA, Braff DL. Realistic expectations of prepulse inhibition in translational models for schizophrenia research.Psychopharmacology (Berl). 2008 Aug;199(3):331-88.View Article

63.Tenback DE, van Harten PN (2011). Epidemiology and Risk Factors for (Tardive) Dyskinesia. International Review of Neurobiology, 98: 211-230.View Article

64.Thiselton DL, Vladimirov VI, Kuo PH, McClay J, Wormley B, Fanous A, Oeill FA, Walsh D, Van den Oord EJCG, Kendler KS, Riley BP (2008). AKT1 Is Associated with Schizophrenia Across Multiple Symptom Dimensions in the Irish Study of High Density Schizophrenia Families. Biological Psychiatry, 63:(5):449-457.View Article

65.Vauquelin G, Bostoen S, Vanderheyden P, Seeman P (2012). Clozapine, atypical antipsychotics, and the benefits of fast-off D 2 dopamine receptor antagonism. Naunyn-Schmiedeberg's Archives of Pharmacology, 385(4):337-372.View Article

66.Villar-Menéndez I, Díaz-Sánchez S, Blanch M, Albasanz JL, Pereira-Veiga T, Monje A, Planchat LM, Ferrer I4, Martín M, Barrachina M (2014). Reduced striatal adenosine A2A receptor levels define a molecular subgroup in schizophrenia. Journal of Psychiatric Research, 51(1):49-59.View Article

67.Wilkinson B, Campbell DB (2013). Contribution of Long Noncoding RNAs to Autism Spectrum Disorder Risk. International Review of Neurobiology, 113(0):35-59.View Article

68.Winchester CL, Pratt JA, Morris BJ (2014). Risk genes for schizophrenia: Translational opportunities for drug discovery. Pharmacology and Therapeutics, 143(1):34-50.View Article

69.Yanagi M, Southcott SA, Shukla AA, Ghose S, Tamminga CA, Joho RH (2014). Kv3.1-containing K+ channels are reduced in untreated schizophrenia and normalized with antipsychotic drugs. Molecular Psychiatry, 19(5):573-579.View Article

70.Yin DM, Chen YJ, Lu YS, Bean JC, Sathyamurthy A, Shen C, Liu X, Lin TW, Smith CA, Xiong WC, Mei L (2013). Reversal of Behavioral Deficits and Synaptic Dysfunction in Mice Overexpressing Neuregulin 1. Neuron, 78(4):644-657.View Article

71.Yu Z, Fang Q, Xiao X, Cao H, Gong N, Yu Z, Xiao X, Wang Y-Z, Xu T-L, Fang Q, Chen Z, Cai Y-Q, Fei J, Hu G (2013). GABA Transporter-1 Deficiency Confers Schizophrenia-Like Behavioral Phenotypes. PLoS ONE, 8(7). DOI: 10.1371/journal.pone.0069883View Article

72.Zhang HX, Zhao JP, Lv LX, Li WQ, Xu L, Ouyang X, Yuan ZQ, Huang JS (2008). Explorative study on the expression of neuregulin-1 gene in peripheral blood of schizophrenia. Neuroscience Letters, 438(1):1-5.View Article

73.Zheng W, Wang H, Zeng Z, Lin J, Little PJ, Srivastava LK, Quirion R (2012). The possible role of the Akt signaling pathway in schizophrenia. Brain Research, 1470(0):145-158.View Article

74.Zvara A, Szekeres G, Janka Z, Kelemen JZ, Cimmer C, Sántha M, Puskás LG. (2005). Over-expression of dopamine D2 receptor and inwardly rectifying potassium channel genes in drug-naive schizophrenic peripheral blood lymphocytes as potential diagnostic markers. Disease Markers, 21(2):61-69.View Article

引用本文

Shunan Li, Benjamin H Lehrman, Hongbao Cao, Lydia C Manor*. Functional network composed of 1,219 genes for Schizophrenia-- a literature data mining and enrichment analysis, Journal of Psychiatry and Brain Science. 2016; 1; (1). https://doi.org/10.20900/jpbs.20160004.

文献评论

相关学者

相关机构